Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside

Messoud Ashina; Jan Hoffmann; Håkan Ashina; Debbie L. Hay; Yadira Flores-Montanez; Thien Phu Do; Roberto De Icco; David W. Dodick

doi:10.1016/j.mayocp.2023.07.003

Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside

Messoud Ashina^*, Jan Hoffmann, Håkan Ashina, Debbie L. Hay, Yadira Flores-Montanez, Thien Phu Do, Roberto De Icco, David W. Dodick

^*Corresponding author for this work

Wolfson SPaRC

Research output: Contribution to journal › Review article › peer-review

3 Citations (Scopus)

Abstract

Migraine is a ubiquitous neurologic disorder that afflicts more than 1 billion people worldwide. Recommended therapeutic strategies include the use of acute and, if needed, preventive medications. During the past 2 decades, tremendous progress has been made in better understanding the molecular mechanisms underlying migraine pathogenesis, which in turn has resulted in the advent of novel medications targeting signaling molecule calcitonin gene–related peptide or its receptor. Here, we provide an update on the rational use of pharmacotherapies for migraine to facilitate more informed clinical decision-making. We then discuss the scientific discoveries that led to the advent of new medications targeting calcitonin gene–related peptide signaling. Last, we conclude with recent advances that are being made to identify novel drug targets for migraine.

Original language	English
Pages (from-to)	285-299
Number of pages	15
Journal	Mayo clinic proceedings
Volume	99
Issue number	2
DOIs	https://doi.org/10.1016/j.mayocp.2023.07.003
Publication status	Published - Feb 2024

Access to Document

10.1016/j.mayocp.2023.07.003

Cite this

@article{dd70adc0a6b749bbb75b84775ddf7266,

title = "Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside",

abstract = "Migraine is a ubiquitous neurologic disorder that afflicts more than 1 billion people worldwide. Recommended therapeutic strategies include the use of acute and, if needed, preventive medications. During the past 2 decades, tremendous progress has been made in better understanding the molecular mechanisms underlying migraine pathogenesis, which in turn has resulted in the advent of novel medications targeting signaling molecule calcitonin gene–related peptide or its receptor. Here, we provide an update on the rational use of pharmacotherapies for migraine to facilitate more informed clinical decision-making. We then discuss the scientific discoveries that led to the advent of new medications targeting calcitonin gene–related peptide signaling. Last, we conclude with recent advances that are being made to identify novel drug targets for migraine.",

author = "Messoud Ashina and Jan Hoffmann and H{\aa}kan Ashina and Hay, {Debbie L.} and Yadira Flores-Montanez and Do, {Thien Phu} and {De Icco}, Roberto and Dodick, {David W.}",

note = "Funding Information: Grant Support: Messoud Ashina was supported by the Lundbeck Foundation Professor grant (R310-2018-3711). Publisher Copyright: {\textcopyright} 2023 Mayo Foundation for Medical Education and Research",

year = "2024",

month = feb,

doi = "10.1016/j.mayocp.2023.07.003",

language = "English",

volume = "99",

pages = "285--299",

journal = "Mayo clinic proceedings",

issn = "0025-6196",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside

AU - Ashina, Messoud

AU - Hoffmann, Jan

AU - Ashina, Håkan

AU - Hay, Debbie L.

AU - Flores-Montanez, Yadira

AU - Do, Thien Phu

AU - De Icco, Roberto

AU - Dodick, David W.

N1 - Funding Information: Grant Support: Messoud Ashina was supported by the Lundbeck Foundation Professor grant (R310-2018-3711). Publisher Copyright: © 2023 Mayo Foundation for Medical Education and Research

PY - 2024/2

Y1 - 2024/2

N2 - Migraine is a ubiquitous neurologic disorder that afflicts more than 1 billion people worldwide. Recommended therapeutic strategies include the use of acute and, if needed, preventive medications. During the past 2 decades, tremendous progress has been made in better understanding the molecular mechanisms underlying migraine pathogenesis, which in turn has resulted in the advent of novel medications targeting signaling molecule calcitonin gene–related peptide or its receptor. Here, we provide an update on the rational use of pharmacotherapies for migraine to facilitate more informed clinical decision-making. We then discuss the scientific discoveries that led to the advent of new medications targeting calcitonin gene–related peptide signaling. Last, we conclude with recent advances that are being made to identify novel drug targets for migraine.

AB - Migraine is a ubiquitous neurologic disorder that afflicts more than 1 billion people worldwide. Recommended therapeutic strategies include the use of acute and, if needed, preventive medications. During the past 2 decades, tremendous progress has been made in better understanding the molecular mechanisms underlying migraine pathogenesis, which in turn has resulted in the advent of novel medications targeting signaling molecule calcitonin gene–related peptide or its receptor. Here, we provide an update on the rational use of pharmacotherapies for migraine to facilitate more informed clinical decision-making. We then discuss the scientific discoveries that led to the advent of new medications targeting calcitonin gene–related peptide signaling. Last, we conclude with recent advances that are being made to identify novel drug targets for migraine.

UR - http://www.scopus.com/inward/record.url?scp=85184278621&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2023.07.003

DO - 10.1016/j.mayocp.2023.07.003

M3 - Review article

C2 - 38180396

AN - SCOPUS:85184278621

SN - 0025-6196

VL - 99

SP - 285

EP - 299

JO - Mayo clinic proceedings

JF - Mayo clinic proceedings

IS - 2

ER -

Pharmacotherapies for Migraine and Translating Evidence From Bench to Bedside

Abstract

Access to Document

Other files and links

Fingerprint

Cite this